Navigation Links
Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
Date:6/9/2009

- PSI-7851 was generally safe and well tolerated in Phase 1a single ascending dose trial

- Further results from single ascending and multiple ascending dose trials are expected in second half 2009

PRINCETON, N.J., June 9 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it had completed the single ascending dose study and begun dosing in a multiple ascending dose trial with PSI-7851, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. This study is designed to assess the safety, tolerability and antiviral activity of PSI-7851 over 3 days in HCV-infected individuals.

"We are encouraged by the safety and pharmacokinetics of PSI-7851 thus far," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "We believe PSI-7851, Pharmasset's lead second generation nucleotide, has the potential to be administered once a day at low milligram doses, while also continuing to demonstrate the many benefits nucleos(t)ides have over other classes of HCV direct acting antivirals, including a high barrier to resistance, pan-genotype potency, and ability to combine with other classes of compounds."

PSI-7851 Phase 1 Program Overview

The Phase 1 program is investigating the safety, tolerability and pharmacokinetics of PSI-7851 in healthy subjects following single doses (Phase 1a) and in patients chronically infected with HCV genotype 1 following repeat dosing for 3 days (Phase 1b). The Phase 1b study will additionally investigate hepatitis C viral dynamics and monitor for the development of drug resistance.

Subjects in the phase 1a single ascending dose study received single doses of PSI-7851 ranging from 25mg to 800mg or a matching placebo. Preliminary data from the phase 1a single ascending
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Pharmassets Underwriters Release Shares from Lock-Up
2. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
3. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
4. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
5. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Present at Two Upcoming Investor Conferences
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset to Present at Deutsche Bank Healthcare Conference
11. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... disorder that dismantles a baby,s immune system is twice as ... 3 million infants says. This is the first evaluation ... treatable condition known as severe combined immunodeficiency (SCID), or "Bubble ... of this condition by the boy in the bubble, who ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the most ... in recent years, developing or acquiring 2 million square ... more than $100 million last year alone. , In ... geographic regions and a wider array of product types ... an enhanced brand identity that includes a new logo, ...
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Systems Operations, Security and, Maintenance ... ARLINGTON, Va., Oct. 16 Vangent, ... and business process outsourcing,solutions, today announced it ... Information and Decision Support (EIDS) Infrastructure,Operations, Security ...
... risk of asthma than their urban counterparts or even ... a University of Alberta study. , Analysis of ... 12 years in the ongoing Canadian National Longitudinal Survey ... in a farming environment had a lower risk of ...
... COLUMBUS, Ga., Oct. 16 Aflac Incorporated,(NYSE: AFL ... financial,results after the market closes on October 23, 2007. ... will,webcast a conference call scheduled for 9:30 a.m. (EDT) ... and CEO Dan,Amos will discuss third quarter results and ...
... STA Travel, the world,s largest student,and youth travel organization, and ... pandemic in Africa. Through the "Good Cents,Initiative", college students across ... to compose a song, direct a video or write an,essay ... where they,will work side by side with Keep A Child ...
... "I would have never,guessed that some of the best ... come from Planned Parenthood, the largest,abortion chain in the ... Days for Life., "People in more than 80 ... about half of the vigils are being conducted outside ...
... is commonly thought that men with low IQs sexually ... deviance, new research has found the men may sexually ... previously taken. , A team of North American ... an intellectual disability and a history of sexual offence ...
Cached Medicine News:Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:Farm kids have lower risk of asthma, study shows 2Health News:Aflac Incorporated to Release Third Quarter Results On October 23, 2007 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 3Health News:40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode 2Health News:'Corrective' sex education may make sexual offenders more dangerous 2
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. (NASDAQ: ... today that results from two clinical studies will be ... the Company,s urine-based diagnostic test for the detection of ... conference is scheduled to take place in ... 25 th . Additionally, a new U.S. patent was ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: